GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FEED · Sep 30, 2025

ENvue Medical, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-25-023542General Corporate
Capex intensity100thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

3.88% · OPTIONAL · VALID

Operating cash generation42thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-272.85% · OPTIONAL · VALID

Revenue growth50thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

92.02% · CORE · VALID

Inventory pressure50thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

310.66% · OPTIONAL · VALID

Gross margin17thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.gross_margin

26.18% · CORE · VALID

Operating margin33thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-311.22% · CORE · VALID

R&D intensity50thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

30.61% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
0.81%
Current
3.88%
Delta
3.07%
Cash Generation Increased
Previous
-684.82%
Current
-272.85%
Delta
411.96%
Growth Increased
Previous
-39.53%
Current
92.02%
Delta
131.56%
Inventory Pressure Decreased
Previous
446.56%
Current
310.66%
Delta
-135.89%
Margin Increased
Previous
-7.08%
Current
26.18%
Delta
33.26%
Profitability Increased
Previous
-804.86%
Current
-311.22%
Delta
493.64%
R And D Intensity Decreased
Previous
196.76%
Current
30.61%
Delta
-166.15%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · FEED Fundamental State →Has State · ENvue Medical, Inc. →Transitioned To · FEED Fundamental State →Transitioned To · FEED CAPEX_INTENSITY_INCREASED →Transitioned To · FEED CASH_GENERATION_INCREASED →Transitioned To · FEED GROWTH_INCREASED →Transitioned To · FEED INVENTORY_PRESSURE_DECREASED →Transitioned To · FEED MARGIN_INCREASED →Transitioned To · FEED PROFITABILITY_INCREASED →Transitioned To · FEED R_AND_D_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.